Kardium, a Vancouver-based medical technology company, has secured US$250 million in an oversubscribed funding round to support the commercial launch of its Globe System, an advanced solution for treating atrial fibrillation (AF). The financing was led by a global group of investors including Janus Henderson Investors, Qatar Investment Authority, MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital, with participation from existing backers such as T. Rowe Price and Durable Capital Partners.
The Globe System features a sophisticated catheter with a 122-electrode array and advanced software, enabling rapid pulmonary vein isolation, high-definition mapping, and targeted ablation anywhere in the atrium—all with a single device. This integrated approach is designed to improve outcomes for patients with atrial fibrillation, a heart rhythm disorder that affects millions worldwide and increases the risk of stroke and heart failure.
CEO Kevin Chaplin emphasized that the new capital will allow Kardium to expand manufacturing, build a commercial team, and pursue regulatory approvals ahead of the Globe System’s anticipated launch later this year. The funding will also support further clinical research and development for additional applications of the technology.
Recent clinical results from the PULSAR study, presented at the 2025 Heart Rhythm Society meeting, showed that 78% of paroxysmal AF patients treated with the Globe System were free from arrhythmia after one year, with zero device-related safety events. Investors highlighted the system’s disruptive potential and strong clinical outcomes as pivotal for the future of AF treatment.
Kardium’s innovation positions it at the forefront of a shift toward pulsed field ablation, offering new hope for patients and advancing the standard of care in cardiac electrophysiology.
